Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | TP53 | P04637 | 7/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2527918 | 0.92 | TP53 (0.43) | MAPTTP53LMNARXFP1PRMT1 | |
| SCHEMBL2531728 | 0.89 | HTT (0.41) | MAPTLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL2534296 | 0.89 | LMNA (0.41) | MAPTTP53LMNARXFP1SMN1; SMN2 | |
| SCHEMBL14331325 | 0.89 | HTT (0.38) | MAPTLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL2537182 | 0.87 | AR (0.40) | MAPTTP53LMNARXFP1SMN1; SMN2 | |
| SCHEMBL2532888 | 0.86 | MAPT (0.46) | MAPTTP53LMNAALDH1A1MAPK1 | |
| SCHEMBL2532337 | 0.86 | SIRT2 (0.44) | MAPTLMNARXFP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL15495157 | 0.85 | DRD2 (0.38) | MAPTLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL2531848 | 0.84 | SCN2B (0.38) | LMNASMN1; SMN2 | |
| SCHEMBL15509981 | 0.84 | MAPT (0.38) | MAPTTP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2558449-B1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-03-05 | — | — | EP | disclosed |
| US-8586747-B2 | 3,3-dimethyl tetrahydroquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2558449-A1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2013-02-20 | — | — | EP | disclosed |
| US-20130023518-A1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | Hoffmann-La Roche Inc (US) | 2013-01-24 | — | — | US | disclosed |
| US-8344137-B2 | 3,3-dimethyl tetrahydroquinoline derivatives | HOFFMAN-LA ROCHE INC. (US) | 2013-01-01 | — | — | US | disclosed |
| WO-2011128251-A1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-20 | — | — | WO | disclosed |
| US-20110257151-A1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | HUA MEDICINE (KY) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257151-A1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | QDPR, PRMT3, PRMT1 | MAPT 3094/4885TP53 3756/4885LMNA 3533/4885 |
| US-20130023518-A1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | QDPR, PRMT3, PRMT1 | MAPT 3094/4885TP53 3756/4885LMNA 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.